Lidocaine Infusion in Pancreatic Cancer

Inclusion Criteria:

1. Has histologically or cytologically confirmed adenocarcinoma of the pancreas that isconsidered resectable as well as other types of pancreatic cancer (malignantendocrine and exocrine tumors)

2. Has measurable disease, defined as at least 1 tumor that fulfills the criteria

3. Patients diagnosed with resectable cancer, but upon initial phase of surgicalexploration found to have metastatic disease

4. Has read, understood and signed the informed consent form (ICF) approved by theIndependent Review Board/Independent Ethics Committee (IRB/IEC)

5. Prior systemic treatments for metastatic disease are permitted, including targetedtherapies, biologic response modifiers, chemotherapy, hormonal therapy, orinvestigational therapy.

Exclusion Criteria:

1. Has American Society of Anesthesiologists (ASA) physical status > 3

2. Has hypersensitivity or allergy to amide-linked local anesthetics

3. Has a second or third degree heart block

4. Has severe sinoatrial block

5. Is currently being treated with any of the following class I antiarrhythmic drugs;quinidine, flecainide, disopyramide, or procainamide

6. Has been treated with amiodarone in the past

7. Has Adams-Stoke syndrome

8. Has Wolff-Parkinson-White syndrome

9. Has a history of blood clots, pulmonary embolism, or deep vein thrombosis unlesscontrolled by anticoagulant treatment

10. Has a known history of human immunodeficiency virus (HIV) positivity or untreatedand uncontrolled hepatitis B or C